The ocular hypertension market has seen robust expansion during the study period with a CAGR of 3.82% [2018-2030], evaluates DelveInsight

0

LAS VEGAS, September 23, 2021 / PRNewswire / – DelveInsights “Ocular Hypertension MarketThe report provides a comprehensive understanding of the historical and predicted epidemiology of ocular hypertension and ocular hypertension market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Ocular Hypertension Market report also includes an analysis of the current Ocular Hypertension Treatment algorithm / practice, market drivers, market barriers, and unmet medical need.

Some of the necessary takeaways from the Market Research Report Eye Hypertension

  • Several major pharmaceutical companies including Novartis, Bausch and Lomb Incorporated, Merck Sharp and Dohme, Aerie Pharmaceuticals, Santen Pharmaceutical, Nicox Ophthalmics and others, develop novel products to improve the treatment prospects for ocular hypertension.
  • In March 2020, Allergan announced that the US FDA had approved Durysta (bimatoprost implant)making it the first intracameral, biodegradable, sustained release implant.
  • The market for ocular hypertension will be subject to continuous change in the coming years due to the increasing population, increased patient awareness and improved diagnostic methods.
  • Several approved therapies such as Durysta, Alphagan-P, Rhopressa, and others will advance the current ocular hypertension therapeutic landscape in the United States and are estimated to increase by 2030.
  • Eye hypertension is complex and has a polygenic base resulting from a combined effect of various common gene variants, each of which has little influence on the disease. Genome-wide association analyzes have identified several loci associated with glaucoma risk factors such as IOP, vertical cup-to-disc ratio, and central corneal thickness.
  • Significant efforts have been made over the past decade to develop new products who use novel approaches to address the unmet needs associated with ocular hypertension. Advances can be seen in the classes of eye drops currently in use, such as: Prostaglandin analogs, rho kinase inhibitors and nitric oxide donors, while there are also new classes of active ingredients, such as tyrosine protein kinase activators. Most of the developing drugs are topical drop formulations, some of which have already been ingested Phase III Try.

For more information on the market impact of therapies, please visit: Ocular Hypertension Drugs Market Analysis

Ocular hypertension is a term used to describe intraocular pressure (IOP) greater than 21 mm Hg in one or both eyes with no clinical signs of optic nerve damage or visual field defect.

DelveInsight estimates the total Common cases of ocular hypertension became 20,817,647 Cases in the 7MM in 2020. Women have also been found to be more affected than men.

the Ocular Hypertension market analysis report offers both historical and forecast epidemiological analyzes, divided into:

  • Total number of predominant cases of ocular hypertension
  • Gender prevalence of ocular hypertension
  • Age-specific prevalence of ocular hypertension
  • Treated cases of ocular hypertension

Get a Complete Breakdown of Epidemiological Segmentation @ Epidemiological analysis of ocular hypertension

Ocular Hypertension Treatment Market

The Ocular Hypertension Market has been categorized according to different classes of therapies available for treatment. These include Prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, alpha agonists, rho kinase inhibitors, and combination therapies.

Prostaglandin Analogs (PGAs) are recommended as the treatment of first line treatment for primary open-angle glaucoma (POAG) due to their effectiveness, limited systemic side effects, and once-daily dosing. Travoprost, Vyzulta, Zioptan are the most commonly prescribed prostaglandin analogs. Before prostaglandins entered the market Beta blockers were well known and loved for glaucoma management.

Combination therapies represent the second highest sales-generating therapy class after the PGAs. The combination of active ingredients from different classes with different mechanisms of action (MoA) is associated with a superior IOP-lowering effectiveness than any single component that is used alone. Fixed combinations of eye drops in Europe contain Prostaglandin analogs and β-blockers, carbonic anhydrase inhibitors and β-blockers, α-2 adrenergic agonists and β-blockers, carbonic anhydrase inhibitors and α-2 adrenergic agonists and β-blockers.

Carbonic anhydrase inhibitors to like Dorzolamid and Trusopt are preferred to oral agents because of their greater site specificity and significantly fewer systemic side effects.

New drugs for ocular hypertension

In the emerging ocular hypertension scenario, several companies are developing therapies for IOP that Rho kinase inhibitors, nitric oxide (NO) donating prostaglandin analogues, ROCK inhibitors, and other. Pharmaceutical companies like Santen Pharmaceuticals, Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia SA de CV, Nicox Ophthalmics and Nicox Ophthalmics develop products with the potential to change the treatment landscape for ocular hypertension. The pharmaceutical products of these companies are currently in the late and medium clinical Stages of development or

The emerging therapies such DE-117 (Santen Pharmaceutical); PDP-716 (Sun Pharma); Sepetaprost (DE-126 / ONO-9054: Santen / Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Ocuphire Pharma) are effective treatments. These drug candidates have shown very promising results, and DelveInsight analysts expected that the completion of clinical development and introduction of these products could increase these companies’ market share in ocular hypertension, in addition to the availability of better management practices for patients with ocular hypertension.

Eye Hypertension Market Dynamics

The eye hypertension market size will increase due to recent advances in therapy, especially intravitreal administration of antiangiogenic agents that have opened new therapeutic perspectives. In addition, a great deal of attention is paid to the imaging of biomarkers Fulfill the unmet need for a better diagnosis of ocular hypertension. It’s been a promising development over the past decade. the Launch of such biomarkers would lead to one significant boost in the forecast years.

Nonetheless, the growth of the ocular hypertension market could be driven by the Ambiguity about the pathophysiology of the disease, Lack of accurate diagnosis, and some effective treatment options available. There is also an unmet need for a wider range of such surgeries to achieve long-term IOP lowering effects, and in more complex cases such as narrow-angle glaucoma and secondary diseases.

scope Eye Hypertension Market Insight Report

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Study period: 3-year historical and 10-year forecast analysis (2018-2030).
  • Ocular Hypertension Market Segmentation: By Region and By Therapies For Ocular Hypertension (Historical And Forecast, Current And In Preparation)
  • Dominant market companies investigating their candidates for ocular hypertension: Novartis, Bausch and Lomb Incorporated, Merck Sharp and Dohme, Aerie Pharmaceuticals, Santen Pharmaceutical, Nicox Ophthalmics, and several others.
  • Analysis: Comparative and joint analysis of new therapies.
  • Case studies
  • Views of KOL
  • Analyst view

Request for a Webex Demo of the Report @ Ocular Hypertension Therapeutics Market

table of contents

1

Important insights into ocular hypertension

2

Introduction to the Ocular Hypertension Report

3

Ocular Hypertension Market Overview at a Glance

4th

Summary of ocular hypertension

5

Background and overview of ocular hypertension

6th

Epidemiology and patient population of ocular hypertension

6.1

The United States

6.2

EU5 countries

6.2.1

Germany

6.2.2

France

6.2.3

Italy

6.2.4

Spain

6.2.5

The UK

6.3

Japan

7th

Treatment of ocular hypertension

8th

NICE recommendations and guidelines

9

Patient journey with ocular hypertension

10

Case reports on ocular hypertension

11

Medications for ocular hypertension

11.1

Travoprost eye drops: Novartis®

11.2

Vyzulta (latanoprostene bunod ophthalmic solution): Bausch and Lomb Incorporated

11.3

Zioptan: Merck Sharp and Dohme

11.4

Rhopressa: Aerie Pharmaceuticals

12th

New therapies for ocular hypertension

12.1

DE-130A (Latanoprost): Santen Pharmaceutical

12.2

NCX 470: Nicox Ophthalmics

13

7MM Ocular Hypertension Market Analysis

13.1

The ocular hypertension market size in the United States

13.2

EU-5 Ocular Hypertension Market size

13.2.1

Germany market size

13.2.2

France market size

13.2.3

Italy market size

13.2.4

Spain market size

13.2.5

The UK market size

13.3

Japan Ocular Hypertension Market Size

14th

KOL views

fifteen

Market driver for eye hypertension

16

Market barriers for eye hypertension

17th

Eye Hypertension SWOT Analysis

18th

Unmet needs

19th

refund

20th

DelveInsight functions

21

Disclaimer of liability

22nd

About DelveInsight

Search the full report with detailed table of contents with charts, figures, tables @ Ocular Hypertension Diagnostics Market Report

View other reports

DelveInsight’s Ocular Hypertension – Epidemiology Forecast 2030 report provides an in-depth understanding of the disease, historical, and predicted epidemiology of ocular hypertension at 7MM.

Ocular Hypertension Pipeline Insights, 2021 report by DelveInsight provides comprehensive insights into the current clinical development scenarios and growth prospects in the Ocular Hypertension Market.

DelveInsight’s report, “Bradycardia Treatment Devices – Market Insights, Competitive Landscape, and Market Forecast – 2026” provides a detailed understanding of Bradycardia Treatment Devices. Important companies that operate in this area are Abbott Laboratories, Biotronik, Boston Scientific, Lepu Medical, Livanova, Medico, Medtronic, Oscor, Osypka Medical, and other.

DelveInsight’s report “Anastomotic Leak Devices – Market Insights, Competitive Landscape and Market Forecast – 2026” provides a detailed understanding of Anastomotic Leak Devices. Important companies that operate in this area are Baxter International Inc. (Synovis Micro Companies Alliance), Medtronic PLC Cryolife, Inc., Getinge AB, Ethicon US LLC. (Johnson & Johnson), Peter Surgical, Becton, and other.

Search blog posts

Above DelveInsight

DelveInsight is a leading management consulting and research firm focused solely on the life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Business advisory services with a credible market analysis that will help accelerate business growth and overcome challenges with a hands-on approach.

Contact us:

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP


Source link

Share.

Leave A Reply